Delivery Order SPE2DB22D3301-SPE2DB26FX3UV
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $7,957.71 to AmerisourceBergen Drug Corp for IMFINZI 500 mg/10 mL vials on August 21, 2025, with completion expected by September 12, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and is performed at the contractor's Conshohocken, Pennsylvania location. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of IMFINZI 500 mg/10 ml vials with a ceiling value of $53,051.40 and a firm fixed price contract type. The order is scheduled for completion by September 29, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. This delivery order was competitively awarded with no set-aside designation and represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of IMFINZI (an oncology medication) in 120 mg/2.4 mL vials with a ceiling value of $6,344.80. This competitively awarded, firm fixed-price contract is non-set-aside and will be performed at AmerisourceBergen's headquarters in Conshohocken, Pennsylvania, with an ultimate completion date of September 17, 2025. The delivery order represents a child contract under...
- The Defense Logistics Agency awarded a $18,567.99 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of IMFINZI 500 mg/10 ml vials. The contract is a non-set-aside competitive award with a completion date of September 23, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (SPE2DX) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of IMFINZI 500 mg/10 mL vials with a ceiling value of $15,915.42. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is to be completed by July 11, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This award is a child contract issued under AmerisourceBergen's larger...
- The Defense Logistics Agency's Medical Supply Chain awarded a $23,873.04 delivery order to AmerisourceBergen Drug Corp on October 16, 2025, for the supply of IMFINZI 500 mg/10 mL vials. This competitively awarded, firm fixed-price delivery order is scheduled for completion by November 6, 2025, and will be fulfilled from the contractor's Conshohocken, Pennsylvania location. The award was made without a set-aside designation, reflecting open competition among qualified vendors. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,957.68 to AmerisourceBergen Drug Corp for IMFINZI 500 mg/10 ml vials. This competitive award, issued on October 24, 2025, with an ultimate completion date of November 17, 2025, represents a firm fixed-price delivery order with no set-aside designation. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $26,525.70 to AmerisourceBergen Drug Corp for the supply of IMFINZI 500 mg/10 mL vials on September 23, 2025, with an ultimate completion date of October 15, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. IMFINZI is a specialized oncology pharmaceutical product, reflecting the...
- The Defense Logistics Agency awarded a delivery order valued at $21,220.56 to AmerisourceBergen Drug Corp for the supply of IMFINZI 500 mg/10 mL vials. This firm fixed price delivery order, issued on September 8, 2025, with an ultimate completion date of September 29, 2025, represents a non-competitive set-aside award to the pharmaceutical distributor. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement and...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,903.44 for IMFINZI (120 mg/2.4 mL vials), an oncology pharmaceutical product. This firm fixed-price, non-set-aside contract was awarded on August 25, 2025, with an ultimate completion date of September 16, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB26FX3UVDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,903.44 to AmerisourceBergen Drug Corp for the supply of IMFINZI (120 mg/2.4 ml vial) on October 24, 2025, with an ultimate completion date of November 17, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, provides an extensive portfolio of pharmaceutical products and medical supplies to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's consistent awards through the DLA Medical Supply Chain demonstrate its capability to meet federal procurement requirements across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and medical devices. This delivery order for IMFINZI, an oncology therapeutic agent, reflects the company's continued role in supplying specialized medications essential to military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 10/24/25 |